This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Flunixin
- DrugBank Accession Number
- DB11518
- Background
Flunixin is a non-steroidal anti-inflammatory drug for use in pigs, cattle and horses. It exerts analgesic and antipyretic effects. This drug is often prepared for use in meglumine salt form. Flunixin is regulated in the United States by the Food and Drug Administration (FDA) and must be prescribed by a licensed veterinarian. Flunixin may be also referred to as Banamine, and other trade names.
- Type
- Small Molecule
- Groups
- Vet approved
- Structure
Structure for Flunixin (DB11518)
- Weight
- Average: 296.249
Monoisotopic: 296.077262091 - Chemical Formula
- C14H11F3N2O2
- Synonyms
- 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)-3-pyridinecarboxylic acid
- Flunixin
- Flunixine
- Flunixino
- Flunixinum
- External IDs
- SCH 14714
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Flunixin may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Abciximab. Acebutolol Flunixin may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Flunixin. Acemetacin The risk or severity of adverse effects can be increased when Flunixin is combined with Acemetacin. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Flunixin meglumine 8Y3JK0JW3U 42461-84-7 MGCCHNLNRBULBU-WZTVWXICSA-N
Categories
- Drug Categories
- Agents causing hyperkalemia
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antipyretics
- Antirheumatic Agents
- Central Nervous System Agents
- Nephrotoxic agents
- Nicotinic Acids
- Non COX-2 selective NSAIDS
- Peripheral Nervous System Agents
- Pyridines
- Sensory System Agents
- Veterinary Drugs
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Trifluoromethylbenzenes
- Direct Parent
- Trifluoromethylbenzenes
- Alternative Parents
- Pyridinecarboxylic acids / Aniline and substituted anilines / Toluenes / Aminopyridines and derivatives / Imidolactams / Vinylogous amides / Heteroaromatic compounds / Amino acids / Secondary amines / Azacyclic compounds show 8 more
- Substituents
- Alkyl fluoride / Alkyl halide / Amine / Amino acid / Amino acid or derivatives / Aminopyridine / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Carboxylic acid show 21 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- organofluorine compound, aminopyridine, pyridinemonocarboxylic acid (CHEBI:76138)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 356IB1O400
- CAS number
- 38677-85-9
- InChI Key
- NOOCSNJCXJYGPE-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H11F3N2O2/c1-8-10(14(15,16)17)5-2-6-11(8)19-12-9(13(20)21)4-3-7-18-12/h2-7H,1H3,(H,18,19)(H,20,21)
- IUPAC Name
- 2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid
- SMILES
- CC1=C(C=CC=C1NC1=C(C=CC=N1)C(O)=O)C(F)(F)F
References
- General References
- Webbon PM, Woolliscroft GJ: Cautious use of flunixin advocated. Vet Rec. 1984 Jul 14;115(2):45. [Article]
- Dobromylskyj P: Intraoperative use of flunixin meglumine. Vet Rec. 1992 Nov 28;131(22):520. [Article]
- Elwood C, Boswood A, Simpson K, Carmichael S: Renal failure after flunixin meglumine administration. Vet Rec. 1992 Jun 27;130(26):582-3. [Article]
- Traub-Dargatz JL, Bertone JJ, Gould DH, Wrigley RH, Weiser MG, Forney SD: Chronic flunixin meglumine therapy in foals. Am J Vet Res. 1988 Jan;49(1):7-12. [Article]
- Hardie EM, Kolata RJ, Rawlings CA: Canine septic peritonitis: treatment with flunixin meglumine. Circ Shock. 1983;11(2):159-73. [Article]
- Jaussaud P: [Flunixin and its use in horses]. Ann Rech Vet. 1986;17(4):353-62. [Article]
- Hardie EM, Hardee GE, Rawlings CA: Pharmacokinetics of flunixin meglumine in dogs. Am J Vet Res. 1985 Jan;46(1):235-7. [Article]
- Ciofalo VB, Latranyi MB, Patel JB, Taber RI: Flunixin meglumine: a non-narcotic analgesic. J Pharmacol Exp Ther. 1977 Mar;200(3):501-7. [Article]
- Hardee GE, Smith JA, Harris SJ: Pharmacokinetics of flunixin meglumine in the cow. Res Vet Sci. 1985 Jul;39(1):110-2. [Article]
- Smitherman P: Intra-operative use of flunixin meglumine. Vet Rec. 1992 Nov 14;131(20):471. [Article]
- External Links
- KEGG Drug
- D04215
- ChemSpider
- 34911
- BindingDB
- 50201618
- 25121
- ChEBI
- 76138
- ChEMBL
- CHEMBL1617398
- ZINC
- ZINC000000001467
- PDBe Ligand
- JBO
- Wikipedia
- Flunixin
- PDB Entries
- 7erd
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0402 mg/mL ALOGPS logP 4.17 ALOGPS logP 3.69 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 1.88 Chemaxon pKa (Strongest Basic) 5.38 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 62.22 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 70.97 m3·mol-1 Chemaxon Polarizability 26.21 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 160.17711 predictedDeepCCS 1.0 (2019) [M+H]+ 162.53511 predictedDeepCCS 1.0 (2019) [M+Na]+ 169.12988 predictedDeepCCS 1.0 (2019)
Drug created at February 26, 2016 17:31 / Updated at February 21, 2021 18:53